Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Neutral 54.3%

Neg 0% Neu 54.3% Pos 0%

Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $11.